Literature DB >> 19021838

Subcortical vascular versus amnestic mild cognitive impairment: comparison of cerebral glucose metabolism.

Sang Won Seo1, Sang Soo Cho, Aram Park, Juhee Chin, Duk L Na.   

Abstract

BACKGROUND AND
PURPOSE: Most studies on mild cognitive impairment (MCI) have been focused on amnestic MCI (aMCI) that is the preclinical stage of Alzheimer's disease (AD). In contrast, only a few studies have involved patients in the preclinical stages of subcortical vascular dementia (subcortical vascular MCI, svMCI). We tried to compare the overall glucose metabolism in patients with svMCI with that of patients with aMCI.
METHODS: We compared the regional metabolic patterns shown on 18 F-FDG (fluro deoxy glucose) positron emission tomography (PET) images from 18 patients with svMCI with those from 25 aMCI patients matched for age, sex, education, and mini-mental state examination (MMSE) score and with those from 35 healthy subjects using a voxel-wise analysis. SPM 2 was used for statistical analysis.
RESULTS: Relative to normal controls, the hypometabolic regions in the aMCI patients were in the bilateral parahippocampal, bilateral posterior cingulate, left superior temporal gyri, left inferior parietal lobule, and right inferior frontal gyrus while those in the svMCI patients were located in the thalamus, insula, superior temporal gyrus, anterior cingulate gyrus, cingulum, right basal ganglia, cerebellum, and brainstem. A direct comparison of glucose metabolism between svMCI and aMCI showed that the glucose hypometabolism in patients with svMCI was more severe in the thalamus, brainstem, and cerebellum.
CONCLUSION: Our study suggested that svMCI was distinct from aMCI in terms of neuropsychological and PET findings, which may explain their clinical manifestations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19021838     DOI: 10.1111/j.1552-6569.2008.00292.x

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  25 in total

1.  Cerebral blood flow by arterial spin labeling in poststroke dementia.

Authors:  M J Firbank; J He; A M Blamire; B Singh; P Danson; R N Kalaria; J T O'Brien
Journal:  Neurology       Date:  2011-04-26       Impact factor: 9.910

2.  Effects of age on the glucose metabolic changes in mild cognitive impairment.

Authors:  Kejal Kantarci; M L Senjem; V J Lowe; H J Wiste; S D Weigand; B J Kemp; A R Frank; M M Shiung; B F Boeve; D S Knopman; R C Petersen; C R Jack
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-18       Impact factor: 3.825

Review 3.  Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia.

Authors:  Peter J Nestor; Daniele Altomare; Cristina Festari; Alexander Drzezga; Jasmine Rivolta; Zuzana Walker; Femke Bouwman; Stefania Orini; Ian Law; Federica Agosta; Javier Arbizu; Marina Boccardi; Flavio Nobili; Giovanni Battista Frisoni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-07       Impact factor: 9.236

4.  Cerebellar atrophy in patients with subcortical-type vascular cognitive impairment.

Authors:  Cindy W Yoon; Sang Won Seo; Jun-Sung Park; Ki-Chang Kwak; Uicheul Yoon; Mee Kyung Suh; Geon Ha Kim; Ji Soo Shin; Chi Hun Kim; Young Noh; Hanna Cho; Min-Jeong Kim; Jong Hun Kim; Jee Hoon Roh; Jong-Min Lee; Duk L Na
Journal:  Cerebellum       Date:  2013-02       Impact factor: 3.847

5.  Early identification of MCI converting to AD: a FDG PET study.

Authors:  Marco Pagani; Flavio Nobili; Silvia Morbelli; Dario Arnaldi; Alessandro Giuliani; Johanna Öberg; Nicola Girtler; Andrea Brugnolo; Agnese Picco; Matteo Bauckneht; Roberta Piva; Andrea Chincarini; Gianmario Sambuceti; Cathrine Jonsson; Fabrizio De Carli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-29       Impact factor: 9.236

6.  Clinical effect of white matter network disruption related to amyloid and small vessel disease.

Authors:  Hee Jin Kim; Kiho Im; Hunki Kwon; Jong-Min Lee; Changsoo Kim; Yeo Jin Kim; Na-Yeon Jung; Hanna Cho; Byoung Seok Ye; Young Noh; Geon Ha Kim; En-Da Ko; Jae Seung Kim; Yearn Seong Choe; Kyung Han Lee; Sung Tae Kim; Jae Hong Lee; Michael Ewers; Michael W Weiner; Duk L Na; Sang Won Seo
Journal:  Neurology       Date:  2015-06-10       Impact factor: 9.910

7.  Amyloid burden, cerebrovascular disease, brain atrophy, and cognition in cognitively impaired patients.

Authors:  Byoung Seok Ye; Sang Won Seo; Geon Ha Kim; Young Noh; Hanna Cho; Cindy W Yoon; Hee Jin Kim; Juhee Chin; Seun Jeon; Jong Min Lee; Joon-Kyung Seong; Jae Seung Kim; Jae-Hong Lee; Yearn Seong Choe; Kyung Han Lee; Young H Sohn; Michael Ewers; Michael Weiner; Duk L Na
Journal:  Alzheimers Dement       Date:  2014-07-19       Impact factor: 21.566

8.  Synergistic effects of ischemia and β-amyloid burden on cognitive decline in patients with subcortical vascular mild cognitive impairment.

Authors:  Mi Ji Lee; Sang Won Seo; Duk L Na; Changsoo Kim; Jae Hyun Park; Geon Ha Kim; Chi Hun Kim; Young Noh; Hanna Cho; Hee Jin Kim; Cindy W Yoon; Byoung Seok Ye; Juhee Chin; Seun Jeon; Jong-Min Lee; Yearn Seong Choe; Kyung-Han Lee; Jae Seung Kim; Sung Tae Kim; Jae-Hong Lee; Michael Ewers; David J Werring; Michael W Weiner
Journal:  JAMA Psychiatry       Date:  2014-04       Impact factor: 21.596

9.  Association between APOE ε2 and Aβ burden in patients with Alzheimer- and vascular-type cognitive impairment.

Authors:  Jin San Lee; Hyejoo Lee; Seongbeom Park; Yeongsim Choe; Yu Hyun Park; Bo Kyoung Cheon; Alice Hahn; Rik Ossenkoppele; Hee Jin Kim; Seonwoo Kim; Heejin Yoo; Hyemin Jang; Soo Hyun Cho; Seung Joo Kim; Jun Pyo Kim; Young Hee Jung; Key-Chung Park; Charles DeCarli; Michael W Weiner; Duk L Na; Sang Won Seo
Journal:  Neurology       Date:  2020-09-14       Impact factor: 9.910

10.  Selective Aberrant Functional-Structural Coupling of Multiscale Brain Networks in Subcortical Vascular Mild Cognitive Impairment.

Authors:  Juanwei Ma; Feng Liu; Bingbing Yang; Kaizhong Xue; Pinxiao Wang; Jian Zhou; Yang Wang; Yali Niu; Jing Zhang
Journal:  Neurosci Bull       Date:  2020-09-25       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.